Cho/Cr ratio at MR spectroscopy as a biomarker for cellular proliferation activity and prognosis in glioma: correlation with the expression of minichromosome maintenance protein 2

Abstract

Background

Magnetic resonance (MR) spectroscopy (¹H-MRS) has been demonstrated to be useful in grading glioma, but the utility in assessing cellular proliferation activity and prognosis correlated with the expression of minichromosome maintenance protein 2 (MCM2) has not been reported.

Purpose

To explore the correlation between proton MR spectroscopy parameters (including choline [Cho]/creatine [Cr], N-acetyl aspartate [NAA]/Cr, and Cho/NAA ratios) and the expression of MCM2 and to further evaluate whether ¹H-MRS can predict cell proliferative activity and provide prognostic information in high-grade gliomas (HGGs).

Material and Methods

Forty-three patients with histopathologically confirmed gliomas were involved in this study. All patients underwent ¹H-MRS examination before surgery. Proliferative activity of gliomas was evaluated by MCM2 labeling index (LI). Pearson correlation analysis and empiric receiver operating characteristic (ROC) curves were performed. The Kaplan–Meier method and Cox regression were used for survival analysis.

Results

Significant correlation was observed between the Cho/Cr ratio and MCM2 LI (r = 0.522, P < 0.01); however, there was no correlation between MCM2 LI and the Cho/NAA or NAA/Cr ratios (r = 0.295, P = 0.55 and r = −0.042, P = 0.788, respectively). According to ROC analysis, MCM2 LI of 50% and Cho/Cr ratio of 2.68 represented the optimized cut-off values, respectively, to distinguish longer or shorter survival than 15 months in HGGs patients. Multivariate analysis revealed that both the Cho/Cr ratio and MCM2 expression were independent prognostic markers.

Conclusion

Cho/Cr ratio has a potential in predicting the expression of MCM2 and can evaluate cell proliferative activity noninvasively. Both the Cho/Cr ratio and MCM2 expression are independent prognostic markers in patients with HGGs.

Keywords

Glioma MCM2 cellular proliferation prognosis

Get full access to this article

View all access options for this article.

References

McNeill

. Epidemiology of brain tumors. Neurol Clin 2016; 34: 981–998.

Louis

Perry

Reifenberger

et al.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803–820.

Hardesty

Sanai

. The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 2012; 3: 140–147.

Stupp

Mason

van den Bent

et al.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996.

Theeler

Yung

Fuller

et al.

Moving toward molecular classification of diffuse gliomas in adults. Neurology 2012; 79: 1917–1926.

Ducray

El Hallani

Idbaih

. Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 2009; 21: 537–542.

Alexiou

Tsiouris

Kyritsis

et al.

Assessment of glioma prolif-eration using imaging modalities. J Clin Neurosci 2010; 17: 1233–1238.

McKeever

Ross

Strawderman

et al.

A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 1997; 56: 798–805.

Giaginis

Vgenopoulou

Vielh

et al.

MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol 2010; 25: 351–370.

10.

Blow

Gillespie

. Replication licensing and cancer–a fatal entanglement? Nat Rev Cancer 2008; 8: 799–806.

11.

Kunnev

Freeland

Qin

et al.

Effect of minichromosome maintenance protein 2 deficiency on the locations of DNA replication origins. Genome Res 2015; 25: 558–569.

12.

Wharton

Chan

Anderson

et al.

Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 2001; 27: 305–313.

13.

Chaumeil

Lupo

Ronen

. Magnetic Resonance (MR) Metabolic Imaging in Glioma. Brain Pathol 2015; 25: 768–780.

14.

Howe

Barton

Cudlip

et al.

Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223–232.

15.

Laskey

Madine

. A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep 2003; 4: 26–30.

16.

Scott

Morris

Rushbrook

et al.

Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. Neuropathol Appl Neurobiol 2005; 31: 455–466.

17.

Hua

Zhao

et al.

Minichromosome Maintenance (MCM) Family as potential diagnostic and prognostic tumor markers for human gliomas. BMC Cancer 2014; 14: 1–8.

18.

Kato

Miyazaki

Fukai

et al.

A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 2003; 84: 24–30.

19.

Kodani

Osaki

Shomori

et al.

Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. J Oral Pathol Med 2003; 32: 468–474.

20.

Fountas

Kapsalaki

Vogel

et al.

Noninvasive histologic grading of solid astrocytomas using proton magnetic resonance spectroscopy. Stereotact Funct Neurosurg 2004; 82: 90–97.

21.

Jin

et al.

Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004; 17: 10–20.

22.

Tolia

Verganelakis

Tsoukalas

et al.

Prognostic value of MRS metabolites in postoperative irradiated high grade gliomas. Biomed Res Int 2015; 2015: 341042–341042.

23.

Lupo

Cha

Chang

et al.

Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma. Am J Neuroradiol 2007; 28: 1455–1461.